Acne Vulgaris
Conditions
Brief summary
The study will be an observational, cross-sectional study of knowledge, understanding, and self-reported behavior among a sample of physicians with recent experience in prescribing Diane-35 or its generics in a total of five European countries. The primary objective of this study is to measure physician knowledge and understanding of the key information contained in the Diane-35 educational material: Patient information card, and Prescribers' Checklist. Specifically, the following objectives will be addressed: * Investigate whether physicians have received any educational material related to Diane-35 or its generics * Assess physicians' knowledge and understanding of key safety information pertaining to the patient information card * Assess physicians' knowledge and understanding of key safety information pertaining to the following areas: * Contraindications relevant to thromboembolism * Risk factors for thromboembolism * Signs and symptoms of thromboembolism
Interventions
DRUGCyproterone acetate 2mg/ethinylestradiol 35 μg (Diane-35)
Cyproterone acetate 2mg/ethinylestradiol 35 μg
Sponsors
RTI Health Solutions
Bayer
Study design
Observational model
OTHER
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
-Physicians eligible to participate will have recently prescribed (e.g., within previous 6 months) Diane-35 or its generics
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The knowledge of the physician concerning Diane-35 | Day1 | The knowledge will be assessed based on a questionnaire with 22 questions which wil assess physician knowledge on key information contained in the Diane-35 educational material including patient information card, prescribers' checklist |
Countries
Austria, Czechia, France, Netherlands, Spain
Outcome results
None listed